Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP®)
Authors:
- Alexander ScheiterASAlexander Scheiter
- Sven MatternSMSven Mattern
- Verena GassenmaierVGVerena Gassenmaier
- Hans-Ulrich SchildhausHSHans-Ulrich Schildhaus
- Matthias ChristgenMCMatthias Christgen
- Hans KreipeHKHans Kreipe
- Hermann HerbstHHHermann Herbst
- Bettina LambertBLBettina Lambert
- Guido SauterGSGuido Sauter
- Maximilian LennartzMLMaximilian Lennartz
- Korinna JöhrensKJKorinna Jöhrens
- Florian SperlingFSFlorian Sperling
Open Access
Abstract
Background: Folate receptor alpha (FRα) is a glycosylphosphatidylinositol-anchored membrane protein encoded by the FOLR1 gene. Its overexpression in various cancers, including ovarian carcinoma, makes it a promising target for antibody-drug conjugates (ADC). Mirvetuximab soravtansine-gynx, an FRα-targeting ADC, has been approved by the FDA and EMA for the treatment of FRα-positive, platinum-resistant ovarian cancer. In the United States, patient selection is tied to the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, an immunohistochemical (IHC) test that identifies tumors with ≥75% moderate-to-strong membrane staining. However, in the European Union, no specific IHC test is mandated, and alternative antibodies are frequently used in routine pathology, necessitating validation of their diagnostic performance. Methods and Results: We report the results of the first interlaboratory proficiency trial on FRα testing conducted by the German Quality Assurance Initiative in Pathology (QuIP®). Sixty-eight pathology institutes participated across internal and open trials using a variety of antibodies and staining platforms. The VENTANA FOLR1 RxDx Assay demonstrated the highest reliability, with 83% of participating laboratories achieving a successful result. In contrast, alternative clones such as BN3.2 (Leica/Novocastra) and EPR20277 (Abcam) showed substantially weaker staining intensity, lower concordance with reference values, and success rates of only 22–25%, while other antibodies failed entirely. Problem analysis revealed that failures with the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay were mainly due to interpretative challenges, whereas weak staining was the predominant issue with alternative clones. Participation in a preparatory online seminar improved pass rates, underscoring the importance of training. Conclusions: These findings highlight the critical importance of standardized, validated assays for FRα detection to ensure accurate patient selection for targeted therapies. The study emphasizes the need for further optimization of alternative antibodies before clinical implementation.Keywords
Funding Information
- AbbVie
This publication has 14 references indexed in Scilit:
- Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancerFuture Oncology, 2025
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerNew England Journal of Medicine, 2023
- FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerClinical Cancer Research, 2023
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA StudyJournal of Clinical Oncology, 2023
- Exploiting the folate receptor α in oncologyNature Reviews Clinical Oncology, 2020
- EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®)Pathology - Research and Practice, 2017
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2017
- Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical OutcomePLOS ONE, 2012
- Folate receptor α regulates cell proliferation in mouse gonadotroph αT3-1 cellsExperimental Cell Research, 2009
- Folate receptor endocytosis and traffickingAdvanced Drug Delivery Reviews, 2004